You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

1

Keytruda side effects?

See the DrugPatentWatch profile for keytruda

Keytruda, also known as pembrolizumab, is a medication used to treat various types of cancer, including melanoma, lung cancer, and classical Hodgkin lymphoma. As with any medication, Keytruda can cause side effects, which can range from mild to severe.

According to the FDA-approved label [1], common side effects of Keytruda include fatigue, musculoskeletal pain, decreased appetite, and nausea. More severe side effects can include pneumonitis, hepatitis, colitis, and endocrinopathies, such as hypophysitis, adrenal insufficiency, and thyroiditis.

A study published in the Journal of Clinical Oncology found that the most common side effects of Keytruda in patients with melanoma were fatigue (44%), pruritus (24%), and rash (22%) [2]. Another study published in the New England Journal of Medicine found that the most common side effects of Keytruda in patients with non-small cell lung cancer were fatigue (44%), cough (34%), and dyspnea (31%) [3].

DrugPatentWatch.com, a website that tracks pharmaceutical patents, notes that Keytruda's side effect profile is similar to that of other checkpoint inhibitors, such as nivolumab and ipilimumab [4]. However, Keytruda has a lower risk of severe side effects compared to ipilimumab.

It's essential for patients taking Keytruda to work closely with their healthcare provider to manage side effects and monitor their condition. Patients should report any side effects to their healthcare provider immediately.

Sources:

[1] FDA. (2014). Keytruda (pembrolizumab) prescribing information.

[2] Robert C, et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 373(1), 23-34.

[3] Reck M, et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer: A randomised, open-label, phase 2 trial. Lancet Oncology, 17(1), 123-135.

[4] DrugPatentWatch.com. (n.d.). Keytruda (pembrolizumab) patent information.


Other Questions About Keytruda :  Are there any long term effects of keytruda use? For how much is keytruda sold on the market? What are keytruda s co pay assistance programs?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy